TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03719131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Receive standard of care ipilimumab therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Receive standard of care ipilimumab therapy
Study: NCT01205516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Patients in the methadone arm will be supplied with 2.5 mg tablets. The dose will consist of 1-12 tablets taken twice daily, every 12 hours (range 5-60 mg per 24 hours).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Controlled Release Morphine
Description: controlled release morphine supplied in 10 mg tablets, 1-12 tablets taken twice daily, every 12 hours (range 20-240 mg per 24 hours).
Study: NCT04101773

Intervention type: PROCEDURE
Group type: OTHER
Intervention: RBL versus sutured mucopexy versus haemorrhoidectomy.
Description: All 3 interventions are part of Dutch usual care, and serve as each other's control.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: RBL versus sutured mucopexy versus haemorrhoidectomy.
Description: All 3 interventions are part of Dutch usual care, and serve as each other's control.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: RBL versus sutured mucopexy versus haemorrhoidectomy.
Description: All 3 interventions are part of Dutch usual care, and serve as each other's control.
Study: NCT00006111

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT00843856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: tacrolimus 2mgs bd adjusted to obtain levels of 5-12ng/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus and mycophenolate mofetil
Description: tacrolimus 2mg bd adjusted to achieve levels of 5-12ng/L mycophenolate mofetil 500mgs bd adjusted to achieve levels of 1.5-3mg/L
Study: NCT03506373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies
Study: NCT03302546

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incremental hemodialysis
Description: Patients randomized to this arm of treatment will be treated during at least 4 hours of hemodialysis twice per week

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional hemodialysis
Description: Patients randomized to this arm of treatment will be treated during at least 3.5 hours of hemodialysis three times per week
Study: NCT01500395

Intervention type: PROCEDURE
Intervention: Hybrid operation
Description: Hybrid Operations including debranching technique+Thoracic Endovascular Aortic Repair (TEVAR), Frozen elephant trunk technique, aortic arch replacement with concommitant TEVAR, et al. Devices include Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）.
Study: NCT01521013

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supported self-care
Description: Subjects will receive a package of depression self-care materials, to include the Antidepressant Skills Workbook, a mood monitoring tool, an informational video on depression, information for family members, and information on additional resources (reading materials, internet sites, community groups).~Subjects will be contacted (by telephone) by their coach, initially at weekly intervals. The frequency of calls will thereafter be mutually determined by subject and coach, but will not exceed weekly calls during the first 3 months, or monthly calls from months 3 to 6. Calls will last an average of 10 minutes. The coach will follow a script to educate/ motivate/guide the subject in the use of the Workbook.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unsupported self-care
Description: Subjects will receive a package of depression self-care materials, to include the Antidepressant Skills Workbook, a mood monitoring tool, an informational video on depression, information for family members, and information on additional resources (reading materials, internet sites, community groups).
Study: NCT02384577

Intervention type: DRUG
Intervention: Budesonide, Formoterol Fumarate Dihydrate
Study: NCT00078572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Capecitabine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the monotherapy arm was 2500 mg/m2 and for the combination arm was 2000 mg/m2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: Capecitabine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the monotherapy arm was 2500 mg/m2 and for the combination arm was 2000 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib (GW572016)
Description: Lapatinib 1250 mg orally once daily
Study: NCT04305574

Intervention type: BEHAVIORAL
Intervention: Use of social media during COVID-19
Description: Participants' self-reported use of an official WhatsApp channel to receive and share news about COVID-19
Study: NCT05565859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planetary Health Plate signage
Description: A Planetary Health Plate graphic was developed based on the healthy reference diet proposed by the Eat Lancet Commission. The graphic was designed to capture the food groups and proportions of food groups promoted by the Planetary Health diet.
Study: NCT04020718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief telephone advice plus tailored text messages
Description: All patients are offered brief advice delivered by telephone by a clinical research coordinator who underwent Tobacco Treatment Specialist core training and a text message program tailored to readiness to quit and quit date. Content is personalized with user's name and Massachusetts General Hospital resources.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief telephone advice plus tailored text messages
Description: All patients are offered brief advice delivered by telephone by a clinical research coordinator who underwent Tobacco Treatment Specialist core training and a text message program tailored to readiness to quit and quit date. Content is personalized with user's name and Massachusetts General Hospital resources.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mailed nicotine replacement therapy
Description: Patients who report continued smoking at Early or Late assessment (depending on random assignment) will be offered a 4 week supply of patches and/or lozenges dosed according to package instructions (patches dosed according to cigarettes smoked per day and lozenges dosed according to time to first cigarette).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mailed nicotine replacement therapy
Description: Patients who report continued smoking at Early or Late assessment (depending on random assignment) will be offered a 4 week supply of patches and/or lozenges dosed according to package instructions (patches dosed according to cigarettes smoked per day and lozenges dosed according to time to first cigarette).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive telephone coaching
Description: Patients who report continued smoking at Early (4-week) or Late (8-week) assessment of response will be randomized to receive proactive telephone coaching or not. Proactive coaching will consist of an attempt to reach the patient by telephone in order to review quit activities, provide information about locally available pharmacologic and behavioral treatment options and information sharing with patient's primary care provider. The coach is trained in core Tobacco Treatment Specialist activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive telephone coaching
Description: Patients who report continued smoking at Early (4-week) or Late (8-week) assessment of response will be randomized to receive proactive telephone coaching or not. Proactive coaching will consist of an attempt to reach the patient by telephone in order to review quit activities, provide information about locally available pharmacologic and behavioral treatment options and information sharing with patient's primary care provider. The coach is trained in core Tobacco Treatment Specialist activities.
Study: NCT02477670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00588302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moexipril
Description: Moexipril was given at a starting dose of 7.5 mg daily for 1 week to all enrolled patients. If tolerated (no clinically significant hypotension or medication associated adverse event), the daily dosage was increased to 15 mg daily at the beginning of the 2nd treatment week. Patients took moexipril orally in the morning and 1 hour prior to food intake. The target dose was maintained for the 1-year period of the study unless the development of toxicities warranted dose reduction or discontinuation.
Study: NCT00369733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Darbepoetin alfa adminstered SC every other week to acheive a Hb not to exceed 12 g/dL
Study: NCT04298788

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blue dishware
Description: blue dishware is used for plates and bowls

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blue dishware
Description: blue dishware is used for plates and bowls
Study: NCT02888457

Intervention type: OTHER
Group type: OTHER
Intervention: Nasopharyngeal sampling with a swab

Intervention type: OTHER
Group type: OTHER
Intervention: Nasopharyngeal sampling with a swab
Study: NCT04310072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: NMES therapy induces visible rhythmic and repeated muscle contractions without volitional effort from the patient by applying electrodes to the thigh and/or calf muscles.
Study: NCT02698891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neulasta
Study: NCT01609517

Intervention type: DRUG
Intervention: Spinal anesthesia (heavy bupivacaine)
Description: Spinal anesthesia with heavy bupivacaine of 6, 7, 8, 9, 10, 11 mg

Intervention type: DRUG
Intervention: Spinal anesthesia (heavy bupivacaine)
Description: Spinal anesthesia with heavy bupivacaine of 6, 7, 8, 9, 10, 11 mg
Study: NCT03239899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants will receive one dose of 2mg/kg of pembrolizumab IV at Week 0.
Study: NCT01468376

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GLU-02
Description: 14 day dosing

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GLU-03
Description: 14 day dosing
Study: NCT03087084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Pacing and Impedance Measurement system
Description: Subjects indicated for Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy Defibrillator device implant will be requested to perform some respiratory manoeuvres while impedance and electrogram signals are recorded by the system
Study: NCT01468376

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GLU-04
Description: 14 day dosing

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GLU-05
Description: 14 day dosing
Study: NCT00904852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tandutinib, bevacizumab, and temozolomide
Description: All patients will have completed treatment with concurrent radiation therapy and temozolomide. Patients will be entered into different dosing groups of tandutinib. Patients will receive up to 6 cycles of treatment with oral temozolomide at 150 mg/m2 daily for the first 5 days of a 28 day cycle, oral tandutinib at escalating doses 250, 375, 500, or 625 mg twice daily on days 1 to 28, and intravenous bevacizumab at 10 mg/kg on days 1 and 15 of each cycle
Study: NCT00554736

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus L-92
Description: Nasal challenge and acoustic rhinometry will be performed at the first study visit and again at the end of the 4-month supplement period. Standardized perennial ryegrass pollen extract (Lolium perenne) (Hollister-Stier, Inc., Spokane, WA) will be used. Dilutions of the standard product will be made in sterile saline prior to use. The standard product strength is 100,000 BAU/mL. Provocation will start with 100 BAU/mL, delivered as a 100 microliter puff into each nostril nose during breath holding, followed by expiration. Acoustic rhinometry, performed in each nostril, will be recorded at 15 minutes. A change of 30% from baseline in the composite score is considered significant. The dose will be increased every 20 minutes if there is no response. The concentrations used will be 100 BAU, 330 BAU, 1000 BAU, 3300 BAU, 10,000 BAU or 33,000 BAU/mL.
Study: NCT02163876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HuCNS-SC cells
Description: surgery arm
Study: NCT01458210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ortho-Cyclen
Description: Administered orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered subcutaneously
Study: NCT04674436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: 6 minute casual walk

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: 6 minute casual walk
Study: NCT02452918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oritavancin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oritavancin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Administered as a concomitant medication at a standard dose and dosing schedule
Study: NCT04525170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HPT treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: untreated
Study: NCT04374110

Intervention type: OTHER
Intervention: Clinical data
Description: Clinical characteristics from medical records
Study: NCT02729558

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: local SRT
Description: local stereotactic radiotherapy in three fractions of 8 Gy to the surgical cavity
Study: NCT00417976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 over 100 minutes every 2 weeks.
Study: NCT01468376

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GLU-06
Description: 14 day dosing
Study: NCT03729154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: First Step
Description: First Step is a comprehensive early intervention that is delivered by a behavioral coach who works in collaboration with the classroom teacher and parents. First Step addresses moderate to severe behavior problems of young children and includes both classroom and home components. The program takes about three months from start to finish and requires approximately 60 hours of the coach's time for implementation over this three month period.
Study: NCT00417976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg every 2 weeks.
Study: NCT01727128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Study: NCT03703037

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound and Doppler ultrasound
Description: Assessment of fetal cerebral and maternal uterine pulsatility index using Doppler ultrasound. Measurement of amniotic fluid index according to four-quadrant technique.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound and Doppler ultrasound
Description: Assessment of fetal cerebral and maternal uterine pulsatility index using Doppler ultrasound. Measurement of amniotic fluid index according to four-quadrant technique.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound and Doppler ultrasound
Description: Assessment of fetal cerebral and maternal uterine pulsatility index using Doppler ultrasound. Measurement of amniotic fluid index according to four-quadrant technique.
Study: NCT01486550

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voluven (Hydroxyethyl starch 130/0,4)
Description: 7,5 ml/kg in the first hour and then 5 ml/kg minimum

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 9mg/ml
Description: 7,5 ml/kg in the first hour and then 5 ml/kg
Study: NCT03071848

Intervention type: OTHER
Intervention: No Intervention
Description: This was an observational study.
Study: NCT01241435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Administered orally
Study: NCT01948960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: everolimus dose escalation
Description: patients with an AUC below mean will have dose escalation of everolimus based on their AUC
Study: NCT04271410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells
Description: CD19 CAR-T cell therapy
Study: NCT03861767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo in doses of 1, 2 and 3 tablets to coincide with the 500, 1000, and 1500 mg arms.
Study: NCT01188499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant
Study: NCT00417976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusional 5-Fluorouracil
Description: 2400 mg/m2 over 48 hours every 2 weeks.
Study: NCT01985009

Intervention type: DEVICE
Group type: OTHER
Intervention: FibroScan® examination.
Description: The study involves adults' patients with suspected Non-Alcoholic Fatty Liver Disease(NAFLD). The FibroScan® is a device equipped with probes (M+ or XL+), each of which consists of an ultrasonic transducer mounted on the axis of a mechanical vibrator. Liver stiffness and CAP measurements are performed on the right lobe of the liver with the patient in a dorsal decubitus and maximal abduction position. The procedure is non-invasive and painless.
Study: NCT04058262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation presential
Description: Facilitator-guided meditation in groups or individually, in 45-minute sessions twice a week for 2 weeks, in a quiet room with controlled light and temperature, and comfortable cushions and chairs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Reiki will be performed in 45-minute sessions twice a week for 2 weeks then in a quiet room with controlled brightness and temperature.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation (app)
Description: Mindfulness meditation guided through 10-15 minute audio using app, to be practiced daily at home.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: round of conversation
Description: The Round of Conversation will take place twice a week, lasting 45 minutes, for two weeks thereafter, at the same clinic, where women will talk about their lives, their needs, how they handle reported situations and how also your skills and preferences.
Study: NCT04973033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: patients enrolled were prescribed tofacitinib 5mg twice a day orally.
Study: NCT00909701

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PreOP Booster
Description: 1 serving of 400 ml per study arm

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PreOP (Nutricia Clinical Care, Trowbridge, UK)
Description: 1 serving of 400 ml per study arm
Study: NCT00817947

Intervention type: DEVICE
Group type: OTHER
Intervention: High frequency chest wall oscillation
Description: Airway clearance using high frequency chest wall oscillation ('The Vest')
Study: NCT01258972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tryton Side Branch Stent with main branch DES
Description: Tryton Side Branch Stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: POBA
Description: Balloon angioplasty
Study: NCT00703755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate /Metformin
Description: fenofibrate 2 x 40 mg bid + metformin 850 mg bid (F160-M1700)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate /Metformin
Description: fenofibrate 2 x 40 mg bid + metformin 500 mg bid (F160-M1000)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate /Metformin
Description: fenofibrate 40 mg bid + metformin 850 mg bid (F80-M1700)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate /Metformin
Description: fenofibrate 40 mg bid + metformin 500 mg bid (F80-M1000)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate /Metformin
Description: fenofibrate 2 x 40 mg bid + metformin placebo (F160-M0)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate /Metformin
Description: fenofibrate placebo + metformin 850 mg bid (F0-M1700)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00148733

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zinc
Description: Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months